ArticleWorld journal of urology2026
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) face a high risk of disease progression. While radical cystectomy (RC) remains the recommended standard of care, many patients are unfit for or unwilling to undergo radical surgery, leading to bladder-sparing strategies spreading in real-world practice. This study aims to describe the oncological outcomes of patients diagnosed with BCG-unresponsive NMIBC treated with gemcitabine/docetaxel (Gem/Doce), electromotive drug administration of mitomycin C (EMDA/MMC), further BCG, or upfront RC.
methodsWe included patients diagnosed with BCG-unresponsive NMIBC treated across 21 European centers (2009–2024) with either intravesical Gem/Doce, EMDA/MMC, further BCG, or upfront RC. Cumulative incidence curves were used to estimate the risk of recurrence, high-grade recurrence, progression, cancer-specific and overall mortality. Multivariable Cox regression models were used to assess the association between treatment type and the risk of recurrence and progression.
resultsOf the 361 patients, 104 (28%) received Gem/Doce, 58 (16%) EMDA/MMC, 150 (42%) further BCG, and 49 (14%) underwent RC. Overall median follow-up was 73 months. Recurrence and high-grade recurrence rates were comparable between Gem/Doce and EMDA/MMC (adjusted HR: 1.30 and 0.40, respectively; both p > 0.5). The 2-year risk of progression was 15% with Gem/Doce, 20% with EMDA/MMC, and 30% with further BCG (p < 0.001). In multivariable analysis, Gem/Doce was associated with a significantly lower risk of progression compared to further BCG (adjusted HR: 0.19, 95% CI 0.09–0.43; p < 0.001). The 2-year cancer-specific mortality was 0% for both Gem/Doce and EMDA/MMC, 4% for BCG, and 7% for RC, with corresponding other-cause mortality rates of 3%, 8%, 11%, and 8%, respectively.
conclusionsIn real-world practice, our study indicates that both Gem/Doce and EMDA/MMC represent viable treatment bladder-sparing options for patients with BCG-unresponsive NMIBC who refuse or are unfit for RC. For patients eligible and consenting to surgery, RC remains the guideline-endorsed standard. Prospective trials are warranted to define the optimal therapeutic algorithm for this challenging patient population.
Indexed as
Identifiers
41521375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.